SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Medical - Drugs >

Apricus Biosciences, Inc. (APRI)

APRI RSS Feed
Add APRI Price Alert      Hide Sticky   Hide Intro
Moderator: carlodb1978, mecosmo2, Chillin up north
Search This Board: 
Last Post: 4/26/2017 8:34:49 PM - Followers: 190 - Board type: Free - Posts Today: 4

Apricus Biosciences, Inc. (APRI) 

 

 

http://www.apricusbio.com/

 

 

 

 

Company Address:

11975 El Camino Real, Suite 300
San Diego, CA 92130
T (858) 222-8041

 CIK:   0001017491

Apricus Website:    http://www.apricusbio.com/index.html

 

 
 

NexACT® - Multi-Route Drug Delivery Technology

NexACT® Multi-Route drug delivery technology facilitates compounds crossing the lipid bilayer and yet biodegrades in vivo to natural amino acids and natural fatty acids.

This technology is useful for:
  • Penetrating, proprietary, topical & transdermal formulations.
    Improving oral bioavailability of poorly soluble, poorly permeating compounds (BCS class 2-4)
    Delivering siRNA therapeutics into the cells; in vivo validated
    Development of more effective, penetrating cosmeceutic formulations
    Preservative

The safety and permeation properties of this proprietary drug delivery technology was demonstrated in the Vitaros® product which was approved for the treatment of erectile dysfunction in November 2010 by Health Canada, and approved by the European Union in June 2013.  Vitaros has been launched in all European Union countries by partner pharmaceutical companies.  Additional agreements for marketing Vitaros have been established.  For more information see the company's most recent 10K SEC filing.

In September 2015 the company anounced an agreement with Allergan to reacquire marketing rights for Vitaros in the U.S.  The company expects to resubmit a filing for FDA approval of Vitaros in the second half of 2016.  For more information see the company's most recent 10K SEC filing.


The company expects to initiate a Phase IIb clinical trial for RayVa to treat Reynaud's Syndrome in the second half of 2016.

In October 2014, the company acquired U.S. development and licensing rights to Fispemifene, a Selective Estrogen-Receptor Modulator (SERM) for treatment of secondary hypogonadism.  In March 2016 the company discontinued development Fispemifene after disappointing Phase IIb results.
.

 Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001017491&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Share Structure:
Outstanding Shares
 61,78M

Authorized Shares
75,000,000
  

Investor Relations:
ir@apricusbio.com
Tel: +1-858 222-8041

Matthew Beck
The Trout Group
:(646)378 2933

 

 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 


                                                                           
Image result for vitaros                                                  

Image result for vitaros

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
APRI
Current Price
Volume:
Bid Ask Day's Range
SureTrader
APRI News: Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) 04/24/2017 04:06:25 PM
APRI News: Current Report Filing (8-k) 04/21/2017 04:20:28 PM
APRI News: Notice of Effectiveness (effect) 04/21/2017 06:01:37 AM
APRI News: Apricus Biosciences Announces Pricing of $7.0 Million Public Offering 04/21/2017 06:00:40 AM
APRI News: Apricus Biosciences Announces Pricing of $7.0 Million Public Offering 04/21/2017 06:00:00 AM
PostSubject
#27255   What makes you think Denner and friends are casinokid11211 04/26/17 08:34:49 PM
#27254   The offering closed today -- I imagine the Bryce Harper 04/26/17 03:26:50 PM
#27253   What's with the volume, are these shares from PuuliTuku 04/26/17 10:05:58 AM
#27252   Rodman & Renshaw Initiates Coverage On Apricus Biosciences Aprilov 04/26/17 08:11:08 AM
#27251   Pascoe lowered the September warrants from .45 to casinokid11211 04/23/17 06:15:39 AM
#27249   Even if they fall below a dollar after OldtimeramI 04/21/17 02:47:12 PM
#27248   No, I don't think so. The show must OldtimeramI 04/21/17 01:54:46 PM
#27247   Apricus Biosciences Announces Pricing of $7.0 Million Public Offering mecosmo2 04/21/17 08:32:03 AM
#27246   Put the nails in the coffin, yes. casinokid11211 04/21/17 06:28:01 AM
#27245   They may be able to limp to the Bryce Harper 04/20/17 07:38:40 PM
#27244   I am wondering if they finally realized that Bryce Harper 04/20/17 07:28:03 PM
#27243   C'mon Denner, put an end to Pascoe, vote casinokid11211 04/19/17 06:09:49 AM
#27242   Pascoe burned 1.6 million in 23 calendar days casinokid11211 04/18/17 05:42:07 PM
#27241   looks like they're spending money on the work OldtimeramI 04/18/17 12:33:22 PM
#27240   looks like they're spending money on the work eicoman 04/17/17 03:42:52 PM
#27239   Finally a company document that actually has the OldtimeramI 04/17/17 10:20:15 AM
#27238   We are offering $6,000,000 of units, consisting of doogdilinger 04/17/17 08:17:47 AM
#27237   On April 17, 2017 , Apricus Biosciences, Inc. (the doogdilinger 04/17/17 08:16:18 AM
#27236   Is everybody sleeping here? No post anymore? It Clariske 04/17/17 01:12:42 AM
#27235   Not only that, but the most popular lot growtheport 04/12/17 10:10:54 PM
#27234   indeed you deserve it! I am looking to Clariske 04/12/17 01:36:50 PM
#27233   Don't know - still wondering why APRI is nsomniyak 04/12/17 12:30:35 PM
#27232   Price manipulation before an offering or some real PuuliTuku 04/12/17 11:21:46 AM
#27231   It seems to me you be right!We must stocktrademan 04/11/17 01:41:06 PM
#27230   It seems to me you be right!We must Clariske 04/11/17 12:41:49 PM
#27229   You could be right that they will end Bryce Harper 04/11/17 12:42:02 AM
#27228   Bryce It would not be the first time that OldtimeramI 04/10/17 01:16:52 PM
#27227   IR told me that the Articles of Incorporation Bryce Harper 04/10/17 10:05:22 AM
#27226   Apricus had an S-1 become effective on 9/28/10 OldtimeramI 04/10/17 01:48:48 AM
#27225   Apricus had an S-1 become effective on 9/28/10 Bryce Harper 04/09/17 11:07:37 PM
#27224   I do find the chart watchers an entertaining growtheport 04/09/17 09:43:50 PM
#27223   APRI bullish 1.70 stocktrademan 04/08/17 03:15:11 PM
#27222   As we all know, the company can raise OldtimeramI 04/08/17 01:54:40 AM
#27221   It is really a damn shame what Pascoe casinokid11211 04/07/17 06:04:52 PM
#27220   Thanks for the reply Old Timer. Bryce Harper 04/07/17 03:19:28 PM
#27219   I don't know about a sliver of hope. OldtimeramI 04/07/17 09:19:15 AM
#27218   Old Timer, a question for you and perhaps Bryce Harper 04/06/17 01:55:36 AM
#27217   What is Pascoe going to do when the casinokid11211 04/04/17 05:34:32 PM
#27216   you may be right mg, you would have eicoman 04/03/17 07:40:49 AM
#27215   There is no doubt that Sarrisa, Anson funds, mean gene 04/02/17 06:04:56 PM
#27214   Thanks oldtimer Aprilov 04/02/17 05:05:39 PM
#27213   it's likely that Denner is at least shorting eicoman 04/02/17 04:53:01 PM
#27212   I don't believe that Denner invested in this OldtimeramI 04/02/17 03:14:49 PM
#27211   Eicoman. Everything is possible. But let's be realists here. OldtimeramI 04/02/17 02:40:58 PM
#27210   it's also possible Denner isn't trading this stock eicoman 04/02/17 01:25:24 PM
#27209   Oldtimer give us a silver lining at least !!!!!! Aprilov 04/01/17 05:29:56 PM
#27208   What I do not understand is why are mean gene 04/01/17 04:34:05 PM
#27207   that makes sense unfortunately eicoman 04/01/17 03:33:34 PM
#27206   I would not be surprised if Denner's hedge OldtimeramI 04/01/17 02:59:30 PM
#27205   I agree that Pascoe has no regard at eicoman 04/01/17 02:23:29 PM
PostSubject